key: cord-0050457-1g4w0cct
authors: Pisetsky, David S.
title: Immune Phenotypes in Individuals Positive for Antinuclear Antibodies: The Impact of Race and Ethnicity
date: 2020-09-22
journal: J Allergy Clin Immunol
DOI: 10.1016/j.jaci.2020.09.006
sha: 41880694120f879fbea637b194e1d0186641e76f
doc_id: 50457
cord_uid: 1g4w0cct

nan

Using an impressive array of immunophenotyping assays, Slight-Webb et al provide important new information on key issues in the pathogenesis of systemic lupus erythematous (SLE): the role of antinuclear antibodies (ANAs); the impact of race and ethnicity on disease susceptibility; and the properties of immune cells regulating autoimmunity (1) . While the study involves only a limited number of patients, the extensive immunophenotyping provides intriguing evidence for a unique immune profile that may determine the transition from normal to aberrant immunity.

As is well known, ANA production is a prominent feature of SLE and related autoantibody associated rheumatic diseases (AARDs) such as Sjogren's syndrome, myositis and systemic sclerosis.

These antibodies bind to DNA, RNA as well as protein complexes of DNA and RNA (2) . Importantly, immune complexes (ICs) between ANAs and their cognate antigens can stimulate the production of type 1 interferon and other cytokines; this stimulation occurs following uptake of ICs into innate immune cells and the interaction of the cargo DNA or RNA with internal nucleic acid sensors. These receptors, which include Toll-like receptors (TLRs), are part of an internal host defense recognizing nucleic acids aberrantly present in the cytoplasm from infection or cell stress.

While some ANAs can have immune activity, the expression of ANAs appears to be widespread in humans. Indeed, as many as 20% of the otherwise healthy individuals can express an ANA as detected by the usual serological assays (3). Among these assays is the immunofluorescence assay (IFA) using HEp-2 cells, long considered the gold standard for ANA detection. ANAs can also be detected by ELISAs as well as ALBIAs (addressable laser bead immunoassays) which are increasingly popular for these determinations because of their high throughput (2) .

The high frequency of ANA positivity in the general population, especially women, is poorly understood although it appears to be rising, perhaps related to environmental factors (3) . Importantly, while the target antigens recognized by ANAs in patients with SLE and other AARDs are well defined J o u r n a l P r e -p r o o f biochemically, the antigens recognized by the otherwise healthy population are, in general, unknown.

As a screening test for early diagnosis or prevention, the ANA assay has great limitations since the false positivity rate is so high. Despite the high frequency of ANA in the populations, SLE only affects about 0.1% of people.

Although most ANA positive individuals will never develop any disease, ANA production is an early event in SLE. ANA production can precede signs and symptoms of disease by five or more years, with more detailed serological analysis demonstrating increasing production of antibodies to nuclear antigens such as DNA, Sm, RNP, Ro and La (4). This stage of disease can be called pre-autoimmunity since symptomatology is not manifest. Along with more diverse ANA production, disturbances of cytokine production can also develop during this stage, perhaps related to the role of ANA ICs in driving cytokine production ( Figure) .

Analysis of immune features of ANA positive individuals without clinical disease is, thus, an important approach to chart the progression of immune system changes leading to autoimmunity (5-7).

As ANAs are the defining feature of SLE and other AARDs, these biomarkers provide a useful probe for mechanisms despite their flaws as screening biomarkers. For their study, Slight-Webb and colleagues performed immunophenotyping of three populations of women: ANA negative healthy, ANA positive healthy and SLE. In view of the increased frequency of SLE and more severe disease in African Americans (AA) compared to European Americans (EA), AA and EA populations were separately analyzed to explore potential reasons for the major differences in disease frequency and course in racial and ethnic populations; these differences include more robust responses to RNA-protein complexes. Each group had 12 patients (1).

The immunophenotyping utilized state-of-the-art techniques: single-cell mass spectrometry; flow cytometry; next generation RNA sequencing; multiplex cytokine profiling; and phospho-signaling J o u r n a l P r e -p r o o f analysis. In addition, serological testing assessed responses to common viruses such as cytomegalovirus, Epstein-Barr virus and herpes simplex virus. This is likely the most detailed analysis ever performed to chart the pathways to autoimmunity.

Since the phenotyping was very extensive, the study produced many interesting findings; two are especially notable. The first finding is that, compared to EA healthy individuals and EA patients with SLE, EA ANA+ healthy individuals had a unique phenotype that was also not observed in AA cohorts. On In studies of this kind, the assay used for ANA detection can influence the populations analyzed.

This study used the BioPlex 2200 © assay for initial screening. This ALBIA measures antibodies to 11 different autoantigens and includes specificities relevant to SLE as well as myositis, Sjogren's syndrome and systemic sclerosis. As such, this approach differs from other studies where an IFA represents the J o u r n a l P r e -p r o o f initial screen. Most healthy subjects who are IFA positive lack antibodies to known antigens relevant to AARDs. In general, the frequency of false positive results with the BioPlex 2200 © is lower than that of the IFA (8), suggesting possible differences in the healthy subjects in this study compared to studies where the IFA was used for ANA screening.

Another potential difference relates to the source of patients. Slight-Webb et al recruited patients from health fairs while other studies have involved subjects evaluated for a positive ANA but found not to have a connective tissue disease (CTD) (7) . A questionnaire was used to rule out a CTD in the Slight-Webb study. Given the complexity of the lupus phenotype, matching populations in terms of demographics and serology is challenging but Slight-Webb et al tried to get as close as possible to comparable populations. Even with the best matching, however, the study provides only one point in time in a process that likely unfolds over many years.

The development of biomarkers to assess pre-autoimmunity is key for strategies for early detection and disease prevention but these biomarkers must be actionable. The ANA itself is inadequate for this purpose since the number of false positive responses (especially in young women) is far too great to allow meaningful detection. A multiplex ANA is perhaps better but, even with assays to As studies on the transition from pre-autoimmunity to autoimmunity advance, it will be important to incorporate other variables such as socio-economic status, nutrition, and the complex ensemble of factors related to race and ethnicity. Only with a more complete accounting of the dimensions of personhood will it be possible to realize the goal of personalized medicine and reduce the health care disparities that make SLE such a serious medical problem. 

Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype

Antinuclear antibody testing: misunderstood or misbegotten?

Increasing Prevalence of

Antinuclear Antibodies in the United States

Development of autoantibodies before the clinical onset of systemic lupus erythematosus

Risk factors for ANA positivity in healthy persons

Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity

The presence of antinuclear antibodies alone is associated with changes in B cell activation and T follicular helper cells similar to those in systemic autoimmune rheumatic disease

ANA as an entry criterion for the classification of SLE

Disease Activity, and Organ Damage: The Black Women's Experiences Living With Lupus (BeWELL) Study